195 related articles for article (PubMed ID: 15286662)
1. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells.
Keeling J; Teng J; Herrera GA
Lab Invest; 2004 Oct; 84(10):1322-38. PubMed ID: 15286662
[TBL] [Abstract][Full Text] [Related]
2. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns.
Teng J; Russell WJ; Gu X; Cardelli J; Jones ML; Herrera GA
Lab Invest; 2004 Apr; 84(4):440-51. PubMed ID: 14990980
[TBL] [Abstract][Full Text] [Related]
3. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo.
Herrera GA; Russell WJ; Isaac J; Turbat-Herrera EA; Tagouri YM; Sanders PW; Picken MM; Dempsey S
Ultrastruct Pathol; 1999; 23(2):107-26. PubMed ID: 10369104
[TBL] [Abstract][Full Text] [Related]
4. In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains.
Isaac J; Kerby JD; Russell WJ; Dempsey SC; Sanders PW; Herrera GA
Amyloid; 1998 Dec; 5(4):238-46. PubMed ID: 10036581
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage.
Keeling J; Herrera GA
Kidney Int; 2005 Oct; 68(4):1590-603. PubMed ID: 16164636
[TBL] [Abstract][Full Text] [Related]
6. Integrated expression of glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light chain-related renal diseases.
Turbat-Herrera EA; Isaac J; Sanders PW; Truong LD; Herrera GA
Mod Pathol; 1997 May; 10(5):485-95. PubMed ID: 9160315
[TBL] [Abstract][Full Text] [Related]
7. Kidney and liver involvement in monoclonal light chain disorders.
Pozzi C; Locatelli F
Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
[TBL] [Abstract][Full Text] [Related]
8. Mesangial cells as amyloid factory: a unique contribution of animal models.
Sirac C; Bridoux F
Kidney Int; 2014 Oct; 86(4):669-71. PubMed ID: 25265948
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal light chain--mesangial cell interactions: early signaling events and subsequent pathologic effects.
Russell WJ; Cardelli J; Harris E; Baier RJ; Herrera GA
Lab Invest; 2001 May; 81(5):689-703. PubMed ID: 11351041
[TBL] [Abstract][Full Text] [Related]
10. An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes.
Teng J; Turbat-Herrera EA; Herrera GA
Kidney Int; 2014 Oct; 86(4):738-46. PubMed ID: 24786709
[TBL] [Abstract][Full Text] [Related]
11. Morphologic heterogeneity of renal light-chain deposition disease.
Gokden N; Barlogie B; Liapis H
Ultrastruct Pathol; 2008; 32(1):17-24. PubMed ID: 18300034
[TBL] [Abstract][Full Text] [Related]
12. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
[TBL] [Abstract][Full Text] [Related]
13. The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis.
Said SM; Best Rocha A; Valeri AM; Paueksakon P; Dasari S; Theis JD; Vrana JA; Obadina MO; Saghafi D; Alexander MP; Sethi S; Larsen CP; Joly F; Dispenzieri A; Bridoux F; Sirac C; Leung N; Fogo AB; McPhail ED; Nasr SH
Kidney Int; 2022 Jan; 101(1):152-163. PubMed ID: 34767832
[TBL] [Abstract][Full Text] [Related]
14. In vitro AL-amyloid formation by rat and human mesangial cells.
Tagouri YM; Sanders PW; Picken MM; Siegal GP; Kerby JD; Herrera GA
Lab Invest; 1996 Jan; 74(1):290-302. PubMed ID: 8569193
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic plasticity of mesenchymal stem cells is crucial for mesangial repair in a model of immunoglobulin light chain-associated mesangial damage.
Herrera GA; Teng J; Zeng C; Xu H; Liang M; Alexander JS; Liu B; Boyer C; Turbat-Herrera EA
Ultrastruct Pathol; 2018; 42(3):262-288. PubMed ID: 29668344
[TBL] [Abstract][Full Text] [Related]
16. [The concurrence of light-chain deposition disease, AL-amyloidosis, and cast nephropathy in a patient with multiple myeloma].
Rekhtina IG; Zakharova EV; Stolyarevich ES; Sinitsina MN; Denisova EN
Ter Arkh; 2015; 87(6):98-101. PubMed ID: 26281203
[TBL] [Abstract][Full Text] [Related]
17. Immunogold quantitation of immunoglobulin light chains in renal amyloidosis and kappa light chain nephropathy.
Silver MM; Hearn SA; Walton JC; Lines LA; Walley VM
Am J Pathol; 1990 May; 136(5):997-1007. PubMed ID: 1693473
[TBL] [Abstract][Full Text] [Related]
18. Crystalline light-chain deposition and amyloidosis in the thyroid gland and kidneys of a patient with myeloma.
Hirota S; Miyamoto M; Kasugai T; Kitamura Y; Morimura Y
Arch Pathol Lab Med; 1990 Apr; 114(4):429-31. PubMed ID: 2108650
[TBL] [Abstract][Full Text] [Related]
19. [Ultrastructural and immunoelectron microscopic study on light chain deposition diseases and primary amyloidosis of the kidney].
Wang S; Zou W; Wang M; Xie Y; Chai L; Tang X
Beijing Da Xue Xue Bao Yi Xue Ban; 2003 Dec; 35(6):576-80. PubMed ID: 14710247
[TBL] [Abstract][Full Text] [Related]
20. Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains.
Teng J; Zhang PL; Russell WJ; Zheng LP; Jones ML; Herrera GA
Nephron Physiol; 2003; 94(2):p28-38. PubMed ID: 12845220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
